Methods in Molecular Biology, Vol. 316: Bioinformatics and Drug Discovery . Edited by Richard S. Larson.

ChemMedChem ◽  
2006 ◽  
Vol 1 (6) ◽  
pp. 654-655
Author(s):  
Matthew P. Jacobson
Keyword(s):  
Drug Discovery ◽  
Molecular Biology

The impact of molecular biology on drug discovery

2006 ◽  
Vol 34 (2) ◽  
pp. 313-316 ◽  
Author(s):  
G.P. Belfield ◽  
S.J. Delaney
Keyword(s):  
Drug Discovery ◽  
Molecular Biology ◽  
Clinical Efficacy ◽  
Drug Targets ◽  
Safety Data ◽  
Vital Role ◽  
Drug Discovery And Development ◽  
New Drug ◽  
Whole Process ◽  
The Impact

The discipline of molecular biology has become increasingly important in recent times for the process of drug discovery. We describe the impact of molecular biology across the whole process of drug discovery and development, including (i) the identification and validation of new drug targets, (ii) the development of molecular screens to find new candidate drugs, and (iii) the generation of safety data and competences leading to enhanced clinical efficacy. We also speculate on emerging developments in drug discovery where it seems likely that molecular biology will play an even more vital role in the generation of future therapies.

scholarly journals Bacteriophage-based tools: recent advances and novel applications

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 2782 ◽  
Author(s):  
Lisa O'Sullivan ◽  
Colin Buttimer ◽  
Olivia McAuliffe ◽  
Declan Bolton ◽  
Aidan Coffey
Keyword(s):  
Drug Delivery ◽  
Drug Discovery ◽  
Molecular Biology ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Bacterial Populations ◽  
Recent Advances ◽  
Novel Applications ◽  
Novel Drug ◽  
Bacterial Control

Bacteriophages (phages) are viruses that infect bacterial hosts, and since their discovery over a century ago they have been primarily exploited to control bacterial populations and to serve as tools in molecular biology. In this commentary, we highlight recent diverse advances in the field of phage research, going beyond bacterial control using whole phage, to areas including biocontrol using phage-derived enzybiotics, diagnostics, drug discovery, novel drug delivery systems and bionanotechnology.

Developing tomorrow's antipsychotics: the need for a more personalised approach

2014 ◽  
Vol 20 (1) ◽  
pp. 3-12 ◽  
Author(s):  
Robert Hunter
Keyword(s):  
Risk Factors ◽  
Differential Diagnosis ◽  
Drug Discovery ◽  
Molecular Biology ◽  
Drug Development ◽  
Environmental Risk ◽  
Response To Treatment ◽  
Long Term Outcomes ◽  
Complex Interplay

SummaryThere has been little pharmacological advance in the treatment of schizophrenia since the introduction of chlorpromazine in the 1950s. This may be set to change as recent advances in molecular biology offer the prospect of a better understanding of the pathophysiology of the disorder and allow investigation of the complex interplay of genetic and environmental risk factors. In this review I discuss future approaches to antipsychotic drug development, highlighting the need to better define symptom areas and develop drugs based on an understanding of neurobiological mechanisms. The development of biomarkers has the potential in future to improve differential diagnosis and help predict response to treatment. These developments herald the possibility of a more integrated drug discovery approach and the subsequent provision of more stratified healthcare, and hopefully significant improvements in patient care and improved long-term outcomes.

Miniaturized screening technologies for drug discovery

2002 ◽  
Vol 30 (4) ◽  
pp. 802-806 ◽  
Author(s):  
J. M. Cooper ◽  
A. E. G. Cass
Keyword(s):  
Drug Discovery ◽  
Molecular Biology ◽  
Pharmaceutical Research ◽  
Toxicity Assessment ◽  
Clinical Development ◽  
Biological Screening ◽  
Drug Candidates ◽  
The Us ◽  
Pharmaceutical Research And Development ◽  
Microsystems Technology

Adaptive Profiling (APL) and other biochip companies aim to harness the power of microsystems technology together with advances in chemistry and molecular biology, to become service and technology providers to organizations involved in pharmaceutical research and development. By supplying a unique range of decisionmaking tools that aid an earlier identification of qualified drug candidates for clinical development, the company should gain a significant share of the US$10 billion biological screening, bioavailability and toxicity assessment market.

CNS drug discovery in the 21st century

1999 ◽  
Vol 174 (S37) ◽  
pp. 23-25 ◽  
Author(s):  
Steven Paul
Keyword(s):  
Drug Discovery ◽  
Molecular Biology ◽  
21St Century ◽  
Neurological Disorders ◽  
New Drugs ◽  
Serotonergic Neurotransmission

The discovery of new drugs for psychiatric and neurological disorders has been greatly facilitated by advances in molecular biology, genetics and chemistry. Several examples are given of how these revolutionary advances have been applied to the discovery of new drugs that selectively modify serotonergic neurotransmission, including compounds which may prove to be more effective antidepressants.

Drug Repurposing in Dermatology: Molecular Biology and Omics Approach

2020 ◽  
Author(s):  
Farid A. Badria ◽  
Abdullah A. Elgazar
Keyword(s):  
Clinical Trials ◽  
Drug Discovery ◽  
Molecular Biology ◽  
Adverse Effects ◽  
Drug Repositioning ◽  
Drug Repurposing ◽  
Pharmaceutical Companies ◽  
Dermatological Condition ◽  
The World ◽  
Initial Discovery

The withdrawal of several blockbuster drugs due to severe adverse effects and the failure of several developed drugs in clinical trials raised questions about the efficacy of current approaches of drug discovery. Moreover, the limitation of resources and the long and costive process of drug discovery made a lot of pharmaceutical companies to employ drug repurposing strategies to get new insights about activities that were not considered during their initial discovery. The development of therapeutics for treatment of dermatological condition is not considered as priority although it affects the lifestyle of thousands of people around the world. Serendipity and observations have contributed significantly in this field but immerse efforts have been exerted to find systematic methods to identify new indications for drugs, especially with the unprecedented progress in molecular biology and omics. So, in this chapter, we will emphasize on different approaches used for drug repositioning and how it was applied to find new therapeutics for different dermatoses.

scholarly journals Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?

2006 ◽  
Vol 8 (3) ◽  
pp. 303-309
Keyword(s):  
Drug Discovery ◽  
Molecular Biology ◽  
Antipsychotic Drug ◽  
Molecular Targets ◽  
Molecular Target ◽  
The Core ◽  
Core Symptoms ◽  
Convincing Data

This review summarizes the various conceptual paradigms for treating schizophrenia, and indicates how molecular biology and drug discovery technologies can accelerate the development of new medications. As yet, there is no convincing data that a crucial druggable molecular target exists which, if targeted, would yield medications with efficacies greater than any currently available. It is suggested, instead, that drugs which interact with a multiplicity of molecular targets are likely to show greater efficacy in treating the core symptoms of schizophrenia.

Sign in / Sign up

Export Citation Format

Share Document